Response to “The importance of determining the limit of detection of non-invasive prenatal testing methods”

2016 ◽  
Vol 36 (9) ◽  
pp. 898-899
Author(s):  
Francesco Fiorentino ◽  
Sara Bono ◽  
Francesca Pizzuti ◽  
Martina Mariano ◽  
Arianna Polverari ◽  
...  
2016 ◽  
Vol 36 (9) ◽  
pp. 896-897 ◽  
Author(s):  
Kai Lüthgens ◽  
Andreas Binder ◽  
Dirk Biskup

2016 ◽  
Vol 36 (4) ◽  
pp. 304-311 ◽  
Author(s):  
Francesco Fiorentino ◽  
Sara Bono ◽  
Francesca Pizzuti ◽  
Martina Mariano ◽  
Arianna Polverari ◽  
...  

2018 ◽  
Vol 2 (2) ◽  
pp. 1-1 ◽  
Author(s):  
Stanislav Birko ◽  
◽  
Marie-Eve Lemoine ◽  
Minh Thu Nguyen ◽  
Vardit Ravitsky ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 562
Author(s):  
Alec J. Kacew ◽  
Glenn J. Hanna

The burden of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has risen, now representing the most common HPV-related malignancy. For years, researchers have explored the utility of measuring HPV-related markers from mouth, throat, and blood samples, often with the aim of gathering more information about an existing HPV-related tumor in a given patient. We review the widely varying methods for collecting and testing saliva and blood samples and offer guidance for standardizing these practices. We then review an array of clinical contexts in which non-invasive testing holds the most promise for potentially addressing unmet needs. In particular, such testing could help clinicians and researchers monitor the effects of vaccination and treatment. Meanwhile, due to the currently incomplete understanding of how carrying HPV relates to infection and subsequent oncogenesis, non-invasive testing methods may not be suitable for the screening setting at this time.


2019 ◽  
Vol 35 (S1) ◽  
pp. 19-19
Author(s):  
Bart Bloemen ◽  
Maarten Jansen ◽  
Wouter Rijke ◽  
Wija Oortwijn ◽  
Gert Vanderwilt

IntroductionHealth Technology Assessment (HTA) is where facts and values meet: the evidence that is considered relevant to the assessment of a technology depends on the value framework used. In the context of the European project VALIDATE (Values in doing assessments of healthcare technologies), we assessed to what extent this interplay between facts and values is acknowledged in HTA reports on non-invasive prenatal testing (NIPT). Our aim is to gain a better understanding of this fact-value relationship, and to contribute to the development of capacity for ethical analyses in HTA.MethodsFive reviewers independently analyzed HTA reports on NIPT, obtained from the National Institute for Health Research (NIHR) HTA database, by answering a structured questionnaire on: (i) arguments, values, and conclusions; (ii) relations between values and collected evidence; (iii) operationalizations of the values involved. Ethical argumentation was analyzed using the method of specifying norms. This method holds that for general, abstract ethical principles to reach concrete cases, principles need to be specified in such a way as to achieve maximal coherence between different value commitments and practice. The results of the analysis were discussed in joint meetings to arrive at a consensus on interpretation.ResultsOur results show that the pivotal role of values in defining what counts as relevant evidence and why, is rarely acknowledged. The same holds for the importance of specifying values as a means to achieve greater coherence between the use of healthcare technologies and a range of values.ConclusionsThere is ample room for improvement in clarifying the role of values in HTA: they can serve to explain and justify what evidence is considered relevant to the assessment of a healthcare technology. Recognizing that abstract values need specification in order to reach concrete cases opens up new opportunities for exploring in what way values are affected by healthcare technologies.


Sign in / Sign up

Export Citation Format

Share Document